Cantor Fitzgerald analyst William Tanner says the FDA designating TherapeuticsMD's TX-004 resubmission as class 2 tacks six months onto the review. TX-004 will likely be launched at least a year after it could have been with a first cycle approval, Tanner tells investors in a research note titled "So That's What The Stock Weakness Was About: FDA Designates Resubmission Class 2." The analyst would not be surprised if last night's news gives bears "something of a sigh of relief." He also believes "yet another financing could be in the cards" for TherapeuticsMD. As such, the analyst lowered his price target for the shares to $28 from $31. Tanner keeps an Overweight rating on the stock.